Genmab — Februar 2019

[polle1]

God morgen

[exitnu]

God morgen

[Hamming]

Sanofi kører videre med ISA + Atezo i solide

[Hamming]

ClinicalTrials.gov

(clinicaltrials.gov)

[Legolas23]

Spændende, hvad de kan med Tecentriq, som Dara fejlede med. Er der nogensinde kommet en endelig konklusion på dette ?

[Bulder]

Kun at den overdødelighed der var i dara-armen (2 pts) ikke skyldtes dara men sygdomsprogression. En forklaring på manglende effekt har vi ikke set - så vidt jeg ved.

[Bulder]

Winkel var på et tidspunkt ude med en teori om at det kunne skyldes (for meget)
dexamethason

[Bulder]

så vidt jeg lige kan se indgår dex ikke i isa-atezo studiet.

[Sukkeralf]

Rart hvis Sanofi kan lave lidt forarbejde og så kan Janssen give den en skalle, når sc dosering er i hus

[E_L]

That is why i would have liked to have seen a bit more feedback ; trying it in lung cancer, with dexamethason might have been a really stupid idea…

[Bulder]

According to Limo Chen's findings lung cancer seemed to be a good idea.

[E_L]

Limo will not have thought about the side effects of the dex. JNJ should have. But all speculation, the chapter is closed until further news.

[Sukkeralf]

Jan said once that if Janssen continued in solid tumours it will be with sc dosing and first after approval i MM - no need to jeopadize with unpleasent deaths in a solid tumour trial

[E_L]

ok, i had not heard that before. That actually makes sense if i am honest.

[Sukkeralf]

The last couples of times he just said that solid tumours are dead - and he will not take any more beating.........poor guy

[Solsen]

I think Jan did say that analyst should put solids to zero because he would avoid that they did write the indication off two times

[Solsen]

JNJ have trials with sc in solids.

[Bulder]

Agree with Solsen. A bit different than saying it's dead.

[Bulder]

In solids? They have in healthy people

[Bulder]

Interesting purpose by the way: to determine whether premedication with corticosteroids is required to improve the tolerability of SC administration of daratumumab in healthy participants.